Pricing
What actually drives the price of GLP-1 medication?
This article has not yet been clinically reviewed.
Ask three telehealth clinics what a month of semaglutide or tirzepatide costs and you'll get three different numbers, sometimes hundreds of dollars apart, for what looks like the same drug. Cash pricing for GLP-1 medication isn't one figure — it's several costs stacked into a single subscription price, and knowing what's actually in the stack is the difference between comparing prices and comparing unrelated things that happen to share a number.
The medication itself
The biggest line item is the medication itself, and it splits two ways. Manufacturer brand-name pens carry patent protection and years of clinical-trial cost built into the list price, which is a large part of why cash-pay brand GLP-1s are priced so far above compounded alternatives. A compounded version, prepared to order by a licensed pharmacy, is not carrying those costs and is a large part of why a compounded plan can be priced so differently from the brand-name pen. What a compounded preparation is — and how it compares to an approved product — is a question for the pharmacy dispensing it and the clinician prescribing it, not something a price comparison settles.
Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality. A lower price does not change that fact, and it is worth restating plainly rather than leaving it implied by the price difference above.
GLP-1 dosing is also not a single strength from day one — it's a titration schedule, starting low and stepping up over several weeks to reduce nausea and other side effects. That means a pharmacy is compounding, labeling and shipping multiple dose strengths across a patient's first few months, not simply refilling one vial on repeat. Every strength in that schedule carries its own compounding and quality-testing cost, so a monthly subscription price has to account for the whole titration arc, not just the maintenance dose a patient eventually settles on.
Clinical oversight, not just the prescription
A meaningful share of the price is not the drug at all — it's the clinical work built around it. A licensed provider reviews the patient's intake, decides whether the medication is appropriate, writes the prescription, and stays reachable to adjust the dose or answer questions as treatment continues. That holds whether the visit happens in an exam room or over telehealth video: the provider's time is a real cost, and a subscription model folds it into the same monthly figure as the medication rather than billing it separately as a consult fee.
Pharmacy, compounding and shipping
Behind the prescription sits a pharmacy that has to be licensed in the patient's state, source active pharmaceutical ingredient it can document the quality of, and ship a temperature-sensitive product in packaging that keeps it stable in transit. Multi-state licensure, cold-chain shipping materials and the testing that verifies each batch all show up somewhere in the price — they just don't show up as their own line item on a monthly invoice.
Why a cash market exists at all
Insurance is the other half of why a cash market exists at all. Many health plans still treat GLP-1 medication prescribed for weight management differently than the same drug prescribed for diabetes, and a number of them require a patient to try other treatments first or decline to cover it at any dose. That leaves a large group of patients paying cash no matter which pharmacy or clinic they choose, which is exactly the situation a subscription-priced model is built to serve: one predictable monthly price in place of a formulary fight.
What that looks like on this site
On Leland, that stack shows up as three plans: semaglutide at $146/mo, tirzepatide at $229/mo, and an oral option at $129/mo for semaglutide — tirzepatide priced separately. Billed monthly on a 6-month plan. The gap between the figures reflects the medication-cost difference described above, not a difference in how much clinical oversight or pharmacy handling any plan includes.
None of this is medical advice, and nothing here recommends one plan over another for any particular person. A qualified clinician determines whether GLP-1 treatment, in any form, is appropriate for you.
